Mortality News and Research

RSS

OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Rising resting heart rate over the years linked to shorter lifespan, study show

Study finds that increases in resting heart rate over time significantly raise mortality risk, underscoring heart rate as a key factor in lifespan determination.

1 Sep 2024

New study confirms safety of SGLT2 inhibitors after acute myocardial infarction

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

1 Sep 2024

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

New research shows that a treatment plan based on novel combination of low doses of three anti-hypertensive drugs in a single pill - known as GMRx2 - was superior to a high-quality standard care treatment plan at lowering blood pressure in patients with uncontrolled hypertension.

1 Sep 2024

RESHAPE-HF2 trial shows M-TEER as effective treatment for functional mitral regurgitation

Mitral transcatheter edge-to-edge repair (M-TEER) reduced cardiovascular death and heart failure (HF)-related hospitalizations with improved health status in patients with HF and moderate to severe functional mitral regurgitation (FMR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Timing of blood pressure medication administration does not affect outcomes

Evening administration of blood pressure (BP)-lowering medications did not reduce the risk of cardiovascular events or death compared with morning administration, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

T-TEER shows promising outcomes in severe tricuspid regurgitation patients after one year

Tricuspid transcatheter edge-to-edge repair (T-TEER) significantly reduced the severity of secondary tricuspid regurgitation and improved quality of life after 1 year, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Research suggests flexible approach to antiplatelet management after drug-eluting stent implantation

Among patients undergoing non-cardiac surgery more than 1 year after coronary drug-eluting stent (DES) implantation, there was no difference with respect to ischaemic outcomes or major bleeding between perioperative aspirin monotherapy and receiving no antiplatelet therapy, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

TAVI outperforms surgery in reducing complications for women with severe aortic stenosis

Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement for reducing death, stroke or rehospitalization in women with severe aortic stenosis, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Study finds no added benefit to routine potassium supplementation after CABG

For the prevention of new-onset atrial fibrillation (AF) after isolated coronary artery bypass graft (CABG) surgery, giving potassium supplements only when levels dropped below the lower limit of normal was non-inferior to routinely supplementing potassium to the upper limit of normal, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

TAVI patients show no benefit from continuing oral anticoagulants

There was no apparent benefit to continuing oral anticoagulants compared with interruption in patients undergoing transcatheter aortic valve implantation (TAVI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

TAVI patients with coronary artery disease can derive benefits from percutaneous coronary intervention

Performing percutaneous coronary intervention (PCI) significantly improved outcomes in patients with stable coronary artery disease (CAD) and severe aortic stenosis selected for transcatheter aortic valve implantation (TAVI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Semaglutide cuts death rates from cardiovascular disease and COVID-19

Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, finds.

30 Aug 2024

Philippines faces scrutiny over rollout of unproven African swine fever vaccine

The Philippines is under global scrutiny as it proceeds with the controlled rollout of an unproven African swine fever (ASF) vaccine from Vietnam amid doubts from experts about its safety and efficacy.

30 Aug 2024

Semaglutide's impact on cardiovascular health expands beyond weight loss

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

Major surgery complications unaffected by use of renin-angiotensin system inhibitors

There was no difference in major post-operative complications in patients who continued vs. stopped renin-angiotensin system inhibitors (RASIs) before non-cardiac surgery, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Finnish study shows 50% reduction in child deaths over 15 years

According to a study by researchers at the University of Oulu, the mortality rate among children and adolescents under the age of 16 dropped by 50 percent between 2005 and 2020.

30 Aug 2024

Fibrin fuels thromboinflammation and brain damage in COVID-19

Researchers reveal fibrin's critical role in COVID-19 by driving thromboinflammation and neuropathology, and highlight a potential antibody therapy to mitigate these effects.

29 Aug 2024

Previous
1
...
11
12
13
14
15
16
17
...
1099
Next

Mortality News and Research

OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Rising resting heart rate over the years linked to shorter lifespan, study show

New study confirms safety of SGLT2 inhibitors after acute myocardial infarction

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

RESHAPE-HF2 trial shows M-TEER as effective treatment for functional mitral regurgitation

Timing of blood pressure medication administration does not affect outcomes

T-TEER shows promising outcomes in severe tricuspid regurgitation patients after one year

Research suggests flexible approach to antiplatelet management after drug-eluting stent implantation

TAVI outperforms surgery in reducing complications for women with severe aortic stenosis

Study finds no added benefit to routine potassium supplementation after CABG

TAVI patients show no benefit from continuing oral anticoagulants

TAVI patients with coronary artery disease can derive benefits from percutaneous coronary intervention

Semaglutide cuts death rates from cardiovascular disease and COVID-19

Philippines faces scrutiny over rollout of unproven African swine fever vaccine

Semaglutide's impact on cardiovascular health expands beyond weight loss

Major surgery complications unaffected by use of renin-angiotensin system inhibitors

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

Vutrisiran shows potential to become the new standard of care for rare heart disease

Finnish study shows 50% reduction in child deaths over 15 years

Fibrin fuels thromboinflammation and brain damage in COVID-19

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News